Photo (l to r): R. Judith Radzan, MD, Peter Cassileth, MD, Miami, Florida, USA
Sep 21, 2011 - There is no significant difference in progression-free survival for patients with indolent B-cell lymphoma treated with rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone along with granulocyte colony-stimulating factor every three weeks or every two weeks, according to a study published online Sept. 19 in the Journal of Clinical Oncology.
Feb 1, 2015
Jan 20, 2012
Mar 18, 2010
May 20, 2013